AzTrials
AzTrials

Locked in SyndromeSpeechBCINCT07698496

Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)

A study testing Chronic speech BCI in people with Locked in Syndrome and ALS (Amyotrophic Lateral Sclerosis), run by University Hospital, Grenoble at 4 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Chronic speech BCI
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3 participants
Where
4 sitesFrance
Study dates
10 Oct 2026to 30 Sep 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female between 18 and 65 years old b. French speaking person c. Person in locked in syndrome with a severe speech disorder following either: i. A subcortical stroke ii. Amyotrophic Lateral Sclerosis. d. Person with stable clinical state (esp. regarding respiratory state) e. Person able to read on a screen (sufficient eye movement control) f. Negative plasma pregnancy test for women of childbearing potential* g. Highly effective or at least acceptable** contraception for women of childbearing potential.
  • Persistence of localizing signals of language function proven by functional MRI.
  • Person able to perform a simple BCI task with MEG j. Person with a neuropsychological profile evaluated by psychiatrist as compatible with sustain BCI training k. Informed consent to participate in the obtained using their usual means and code of communication (residual vocalizations, eye-blinking code, pictograms, eye tracking, alphabet chart, etc.), in the presence of their trusted person or curator who is accustomed to communicating with them using this means.
  • Person affiliated to the French social security system or beneficiary of such a system

Who cannot join

  • Patients with any of the following criteria cannot be included in this investigation:
  • Severe cognitive disorders assessed after a neuropsychological evaluation
  • Deafness
  • Continuous assisted ventilation
  • Contraindication to intracranial surgery
  • Contra-indication to MRI (1.5T), CT-scan or their related contrast agent injection or MEG examinations.
Show all 11Show fewer
  • Anatomical brain MRI showing structural abnormalities in the cortical areas of language
  • Functional impairment of language cortical areas on MRI
  • Auditory evoked potential showing hearing impairment
  • Person with a skull shape incompatible with one WIMAGINE implant on each hemisphere
  • Persons referred to in Articles L1125-7 of the Public Health Code and article 64 of MDR(corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, minors, persons deprived of liberty by judicial or administrative decision.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

France4 sites
  • Hôpital Raymond Poincaré Garches

    Garches, 92380

    Jonathan LEVY, Doctor, (33) 1 47 10 70 86, jonathan.levy2@aphp.fr

    Amina FONTANELL, (33) 4 56 52 03 89, lafontanell@chu-grenoble.fr

  • Centre hospitalier Grenoble

    Grenoble, 38000

    Amina FONTANELL, (33) 4 56 52 03 89, lafontanell@chu-grenoble.fr

    Blaise Yvert, (33) 6 32 88 75 90, blaise.yvert@inserm.fr

  • Centre hospitalier Nimes

    Nîmes, 30900

    Simon BERTRAND, Doctor, (33) 4 66 68 34 59, simon.bertrand@chu-nimes.fr

    Amina FONTANELL, (33) 4 56 52 03 89

  • Centre hospitalier saint Etienne

    Saint-Etienne, 42100

    Lydia OUJAMAA, Doctor, (33) 4 77 12 03 34, lydia.oujamaa@chu-st-etienne.fr

    Amina FONTANELL, (33) 4 56 52 03 89, lafontanell@chu-grenoble.fr

Other trials in France

About this study

Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. The quality of life of people with LIS depends strongly on their ability to communicate, and speech synthesis is the mode of communication restoration most desired by individuals with LIS. Several surveys have shown that improving communication abilities in these individuals leads to a significant improvement in their quality of life as well as that of their caregivers.

Natural speech allows the production of an average of 150 words per minute. Non-invasive communication methods, whether based on residual motor function (eye-blink code) or on brain-machine or brain-computer interfaces (Brain-Computer Interface, BCI) using scalp electroencephalographic (EEG) signals, involve a high cognitive load and have low efficiency (spelling only a few letters per minute). Invasive BCIs for speech rehabilitation aim to overcome the limitations of non-invasive devices (cognitive overload and slow speech rate). The intention to act (the act of speaking) is predicted by an algorithm based on the direct decoding of neuronal activity from the sensorimotor cortex (the area where articulatory muscles are represented).

Read more

To date, studies testing speech rehabilitation BCIs in humans remain rare. A subdural electrocorticographic (ECoG) invasive BCI enabled speech decoding (words and sentences from a limited repertoire) for chronic use (2 years). Real-time control of an on-screen cursor allowing spelling of up to 90 letters per minute (equivalent to text messaging) has also been achieved using an intracortical invasive BCI (Utah Array). Very recently, up to 60 words per minute were produced using an intracortical invasive BCI (Utah Array) implanted in the ventral premotor cortex, although with a connector potentially contaminated by acoustic audio feedback. Furthermore, these devices still rely on transcutaneous connectors, which may be sources of infection and prevent routine daily-life use.

In summary, there is currently no fully implantable, wireless invasive "speech BCI" with real-time speech synthesis suitable for long-term home use. The present study will use an intracranial extradural invasive BCI combined with a speech synthesizer, with the aim of developing a communication tool suitable for everyday use. More specifically, the SpeechBCI protocol will propose two complementary BCI approaches in the same subject: a speech BCI (primary objective, BCI_PAROLE device) and a cursor BCI (secondary objective). Both BCIs will use the WIMAGINE intracranial epidural system, enabling ECoG signal acquisition with a very limited risk of infection and brain injury and providing signals that are more stable over time compared with intracortical or subdural ECoG devices that retain transcutaneous connectors. These systems will allow long-term and ecological use, as the WIMAGINE implant is wireless and offers excellent long-term signal stability. The WIMAGINE implant has already been successfully tested for controlling an exoskeleton in a tetraplegic subject (operational for over 6 years) and very recently for controlling walking in real-life conditions via a spinal cord stimulator in a paraplegic individual.

The BCI_PAROLE device will integrate a speech synthesizer providing real-time auditory feedback to the speaker. The BCI-CURSEUR device will allow the subject to control an on-screen cursor to access various communication functionalities (web access, emails, chats, etc.). This will provide a complementary communication solution to real-time speech production.

The hypothesis of this stydy is that the intention to speak (attempted speech) will be decoded by the BCI_PAROLE device in individuals with LIS because, as with limb paralysis, paralysis of articulatory and phonatory muscles does not prevent the corresponding cortical map from producing specific signals. Similarly, the BCI-CURSEUR device will decode the intention to move a cursor and perform actions on a computer screen.

Neuronal electrical signals will be recorded bilaterally from the ventral motor cortex (representation of lips, cheeks, tongue, palate, and larynx-the vocal tract) and from the dorsal part of the motor cortex (larynx and hand, the latter for controlling a two-degree-of-freedom cursor), using a total of 128 electrodes (64 on each cerebral hemisphere). The implant will be optimally positioned over speech motor areas using preoperative functional imaging in order to optimize speech decoding by the BCI_PAROLE device.

Being tested
Chronic speech BCI
Keywords
Locked in syndrom, Speech disorders, Brain-computer interface, BCI, speech rehabilitation
Medical subject headings
Locked-In Syndrome, Amyotrophic Lateral Sclerosis, Speech Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chronic speech BCIDevice

    Chronic speech BCI

Study groups in NCT07698496
Study groupRoleWhat they receive
The subject serves as their own control in a crossover design.ExperimentalChronic speech BCI
Receives: Device: Chronic speech BCI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. safety of the implant

    Serious adverse events associated with chronic implantation with an extradural ECoG implant, especially infection, chronic pain and neurological complication.

    Measured: 2 years after surgery

  2. Faisability of the SpeechBCI

    Successful real-time synthesis of at least 20 different intelligible speech items (vowels, words or short sentences) above chance level from brain activity after 12 months training post-implantation.

    Measured: 1year after surgery to 2 years after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2026
  2. Study start10 Oct 2026 (estimated)
  3. Primary completion30 Jan 2031 (estimated)
  4. Study completion30 Sep 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Model description
The investigation will consist in a series of 3 controlled N-of-1 trials. In this experimental design, each patient will be his/her own control.
Masking
None (open label)
Enrolment
3 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07698496
Sponsor's protocol ID
38RC23-0266
Acronym
SpeechBCI
Status last verified
Jul 2026
First submitted
2 Jun 2026
Last updated
13 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Chronic speech BCI in people with Locked in Syndrome and ALS (Amyotrophic Lateral Sclerosis), run by University Hospital, Grenoble at 4 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amina FONTANELL ((33) 456520389, lafontanell@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

safety of the implant (time frame: 2 years after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in